Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s fifth inclusion on the list. Ranked 16th, Eisai was the highest ranking company among global pharmaceutical companies. Also, Eisai became the highest ranking Japanese company among the five Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 8,100 of the world’s major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davosweek. The Global 100 is based on up to 24 key performance indicators covering clean revenue, financial management, supplier performance, employee managementand resource management, with the evaluations carried outbased on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment*, as well as employee safety and stability.

Eisai’s corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate valueby strengthening its ESG initiatives andincreasing non-financial value.

*Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.

 

Media Inquiries:
Public Relations Department, 
Eisai Co., Ltd.
+81-(0)3-3817-5120

Type Press Release

Date Released January 26, 2021

RECENT RELEASES
Apr 12, 2024

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's...

Mar 31, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Mar 5, 2024

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields